Giannelli Alessio, Brianti Emanuele, Varcasia Antonio, Colella Vito, Tamponi Claudia, Di Paola Giancarlo, Knaus Martin, Halos Lénaïg, Beugnet Frederic, Otranto Domenico
Dipartimento di Medicina Veterinaria, University of Bari, Bari, Italy.
Dipartimento di Scienze Veterinarie, University of Messina, Italy.
Vet Parasitol. 2015 Apr 30;209(3-4):273-7. doi: 10.1016/j.vetpar.2015.02.037. Epub 2015 Mar 12.
The increasing reports of Aelurostrongylus abstrusus infection and the new information on Troglostrongylus brevior have spurred the interest of the scientific community towards the research of pharmaceutical compounds effective against both pathogens. A novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel (Broadline®, Merial) has been released for the treatment of a variety of feline parasitic infections. The present study reports the efficacy of this spot-on in treating cats naturally infected by feline lungworms. Client owned cats (n=191) were enrolled from three geographical areas of Italy and faecal samples were examined by floatation and Baermann techniques. Twenty-three individuals were positive for L1 of A. abstrusus (n=18) or T. brevior (n=3) or for both species (n=2) and they were topically treated with Broadline®. Seventeen of them were also concomitantly infected by other parasites. Four weeks after treatment, faecal samples were collected and examined to assess the efficacy of a single administration of the product. Based on lungworm larvae counts, the efficacy of the treatment was 90.5% or 100% for A. abstrusus or T. brevior, respectively. Cats released significantly lower amounts of lungworm larvae after treatment compared to pre-treatment (p<0.0001). All but three cats were negative for other nematodes after treatment and all cats recovered from respiratory signs. Results of this study indicate that a single administration of the topical combination fipronil, (S)-methoprene, eprinomectin and praziquantel is effective and safe for the treatment of A. abstrusus and/or T. brevior infections in cats living under field conditions.
猫隐孢子虫感染报告的不断增加以及短尾管圆线虫的新信息激发了科学界对研究有效对抗这两种病原体的药物化合物的兴趣。一种新型的氟虫腈、（S）-烯虫酯、埃普利诺菌素和吡喹酮的局部用组合制剂（博来恩®，梅里亚公司）已获批用于治疗多种猫寄生虫感染。本研究报告了这种滴剂在治疗自然感染猫肺线虫的猫方面的疗效。从意大利的三个地理区域招募了191只客户拥有的猫，并通过漂浮法和贝尔曼技术检查粪便样本。23只个体的粪便样本中检测到猫隐孢子虫（n = 18）或短尾管圆线虫（n = 3）的L1期阳性，或两种线虫均呈阳性（n = 2），对它们进行了博来恩®局部治疗。其中17只也同时感染了其他寄生虫。治疗四周后，收集粪便样本并进行检查，以评估单次给药该产品的疗效。根据肺线虫幼虫计数，治疗对猫隐孢子虫或短尾管圆线虫的疗效分别为90.5%或100%。与治疗前相比，治疗后猫排出的肺线虫幼虫数量显著减少（p<0.0001）。治疗后，除三只猫外，所有猫的其他线虫检测均为阴性，所有猫的呼吸道症状均已恢复。本研究结果表明，单次局部使用氟虫腈、（S）-烯虫酯、埃普利诺菌素和吡喹酮的组合制剂对野外条件下生活的猫感染猫隐孢子虫和/或短尾管圆线虫有效且安全。
